EUCTR2014-000074-19-IT进行中（未招募）1 期
Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematological Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must be 12-65 years of age
- •2. Patients with one of the following hematologic malignancies:
- •Acute lymphoblastic leukemia (ALL) at one of the following stages:
- •a. High risk first complete morphologic remission (CR1), defined as one or more of the following:
- •The presence of t(4;11), t(9;22), t(1;19) or MLL rearrangements t(11q23)
- •Extreme leukocytosis (WBC >30,000/µl for B-ALL or >100,000/µl for T-ALL)
- •Longer than 4 weeks to achieve complete remission after induction therapy
- •b. Second or subsequent remission
- •Acute myelogenous leukemia (AML) at one of the following stages:
- •a. First complete morphologic remission (CR1) that is NOT considered as favorable-risk:
- •Favorable risk is defined as having one of the following:
- •- t(8,21) without cKIT mutation
- •- inv(16) without cKIT mutation or t(16;16)
- •- Normal karyotype with mutated NPM1 and no FLT-3 Internal Tandem Duplication
- •- Normal karyotype with double mutated CEBPA
- •- APL in first or second molecular remission at end of consolidation
- •b. Second or subsequent remission
- •Chronic myelogenous leukemia (CML) at one of the following phases:
- •a. Chronic phase with one or more of the following characteristics:
- •- Failure to achieve a primary hematologic or cytogenetic response to either nilotinib or dasatinib (following European LeukemiaNet timelines)
- •- Intolerance to/failure of two tyrosine kinase inhibitors (TKI)
- •- Any T3151 mutation
- •b. Accelerated phase with one or more of the following characteristics:
- •- Newly diagnosed patients who do not achieve an optimal response to TKIs
- •- TKI-treated patients who progress from chronic phase
- •c. Blast crisis (myeloid or lymphoid) with disease control
- •Myelodysplastic Syndrome (MDS) with International Prognostic Scoring System (IPSS) risk category of INT-1 or greater and <5% myeloblasts in the bone marrow on morphologic analysis. MDS patients categorized as INT-1 on primary presentation must have life threatening neutropenia or thrombocytopenia.
- •Lymphoma fulfilling one of the following criteria:
- •a. Chemotherapy-sensitive (complete or partial response) lymphomas that have failed at least 1 prior regimen of multi-agent chemotherapy and are INELIGIBLE for an autologous transplant.
- •b. Marginal zone B-cell lymphoma or follicular lymphoma that has progressed after at least two prior therapies (excluding single agent Rituxan).
- •3.Patients must have a partially HLA-matched CBU: the unit must be HLA-matched at 4-6/6 HLA class I (HLA-A & HLA-B, low resolution) and II (HLA-DRB1, high resolution) loci with the patient. The CBU must have a pre-cryopreserved, total CD34+ cell dose of =10 x10^6 as well as a pre-cryopreserved total nucleated cell dose of =1.8x10^9 and =1.8x10^7 TNC/kg. The CBU will have undergone volume reduction (both plasma and red blood cell depletion) prior to cryopreservation.
- •4.Patients must have an additional partially HLA-matched CBU, or two CBUs, reserved as a backup in case of batch failure. The backup CBU/s must be HLA-matched at 4-6/6 HLA class I (HLA-A & HLA-B, low resolution) and II (HLA-DRB1, high resolution) loci with the patient, and must have a pre-cryopreserved, total nucleated cell dose of at least 2x10^7 per kilogram, in case of one CBU, or 3x10^7 per kilogram, in case of two CBUs.
- •5. Patients must have a related, haplo-identical family member who is suitable for bone marrow or peripheral blood stem cell donation and has agreed to do so in the event of graft failure.
- •6. Subjects
排除标准
- •1. NK cell lymphoma, Burkitt's lymphoma
- •2. CLL/SLL diagnosis
- •3. MDS or CML with marked or 3+ fibrosis
- •4. Less than 21 days have elapsed since initiation of the patient's last chemotherapy regimen and the initiation of the stem cell transplant preparative regimen (intrathecal agents, hydroxyurea, tyrosine kinase inhibitors, hypomethylating agents and rituximab, not considered chemotherapy)
- •5. Persistent clinically significant toxicities from prior chemotherapy that, in the investigator?s opinion, make the patient unsuitable for transplant
- •6. Evidence of anti-HLA antibodies to the selected NiCord® CBU (MFI>3000)
- •7. Evidence of HIV infection or HIV positive serology
- •8. Evidence of active Hepatitis B, Hepatitis C or EBV as determined by serology or PCR
- •9. Pregnancy (ßHCG +) or lactation
- •10. Active malignancy other than that for which the UCB transplant is being performed within 12 months of enrollment. Fully resected cutaneous squamous cell or basal cell carcinoma or cervical carcinoma in situ within 12 months of enrollment will be permitted.
- •11. Evidence of uncontrolled bacterial, fungal or viral infections or severe concomitant diseases, which in the judgment of the Principal Investigator indicate that the patient could not tolerate transplantation
- •12. Patients with signs and symptoms of active central nervous system (CNS) disease, including CNS leukemia or lymphoma
- •13. Patients with an 8/8 allele level HLA-matched and readily available related or unrelated donor, e.g. patients who have haploidentical related donors will not be excluded
- •14. Prior allogeneic hematopoietic stem cell transplant
- •15. Allergy to bovine, gentamicin, or to any other product which may interfere with the treatment
- •16. Psychiatric illness and/or social situations that would limit compliance with study requirements
- •17. Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by Sponsor
研究者
相似试验
已完成
2 期
Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematological Malignanciesbone marrow cancer10024324leukemiaNL-OMON43606Gamida Cell ltd.5
进行中（未招募）
1 期
Transplantation of NiCord, stem cells from donated umbilical cord blood that were grown in a laboratory to expand their number, in adolescent and adult patients with cancers of the blood and lymphHigh risk haematological malignanciesMedDRA version: 17.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10025316Term: Lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864EUCTR2014-000074-19-NLGamida Cell Ltd20
进行中（未招募）
1 期
Transplantation of CordIn, stem cells from donated umbilical cord blood that were grown in a laboratory to expand their number, in patients with a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin moleculeHemoglobinopathiesMedDRA version: 18.0Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 18.0Level: LLTClassification code 10040645Term: Sickle cell disease NOSSystem Organ Class: 100000004850EUCTR2014-003572-23-FRGamida Cell Ltd15
已完成
1 期
Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With HemoglobinopathiesSickle Cell Disease & ThalassemiaNCT01590628Gamida Cell ltd16
已完成
1 期
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)Non-Hodgkin's LymphomaHodgkin's DiseaseNCT01221857Gamida Cell ltd12